A bit more
$MIRA Pharmaceuticals (MIRA.US)$ Mira Pharmaceuticals Announces Selection Of Neuropathic Pain As Indication For Ketamir-2 And Submits Pre-IND Meeting Request To FDA
Benzinga· 1 min ago
Mira Pharmaceuticals, Inc. (NASDAQ:MIRA) today announced that it has selected neuropathic pain as the primary indication for its novel oral ketamine analog, Ketamir-2. The Company has submitted a pre-Investigational New Drug (pre-IND) meeting request to the U.S. Food and Drug Administration (FDA) and anticipates the meeting to occur in October 2024. This selection marks a significant milestone as Mira Pharmaceuticals advances toward its IND submission, with plans to begin human trials in the first quarter of 2025.
Benzinga· 1 min ago
Mira Pharmaceuticals, Inc. (NASDAQ:MIRA) today announced that it has selected neuropathic pain as the primary indication for its novel oral ketamine analog, Ketamir-2. The Company has submitted a pre-Investigational New Drug (pre-IND) meeting request to the U.S. Food and Drug Administration (FDA) and anticipates the meeting to occur in October 2024. This selection marks a significant milestone as Mira Pharmaceuticals advances toward its IND submission, with plans to begin human trials in the first quarter of 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
